What is Dostarlimab?
Business Standard - 07 May 2025What is Dostarlimab? ...
dostarlimab
What is Dostarlimab? ...
Dostarlimab Yields High cCR Rates and Organ Preservation in Early-Stage dMMR Tumors
OncLive - 09 May 2025Dostarlimab Yields High cCR Rates and Organ Preservation in Early-Stage dMMR Tumors ...
Jemperli (dostarlimab), MAH: GlaxoSmithKline (Ireland) Limited
European Commission - 08 May 2025Jemperli (dostarlimab), MAH: GlaxoSmithKline (Ireland) Limited ...
FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer
Targeted Oncology - 16 Dec 2024FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer ...
Pipeline
GSK - 30 Apr 2025Pipeline ...
A New Immune Treatment May Work Against Several Cancer Types
Time Magazine - 28 Apr 2025A New Immune Treatment May Work Against Several Cancer Types ...
Dostarlimab Combo Earns Expanded European Approval in Endometrial Cancer
Cancer Network - 20 Jan 2025Dostarlimab Combo Earns Expanded European Approval in Endometrial Cancer ...
Nonoperative Management of Mismatch Repair–Deficient Tumors
The New England Journal of Medicine - 27 Apr 2025Nonoperative Management of Mismatch Repair–Deficient Tumors ...
Immunotherapy helps certain cancer patients avoid surgery: ‘We hope this is the future’
CNN - 05 May 2025Immunotherapy helps certain cancer patients avoid surgery: ‘We hope this is the future’ ...
Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors
The Cancer Letter - 02 May 2025Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors ...
Neoadjuvant Dostarlimab Eradicates Disease in 82% of Mismatch Repair–Deficient Solid Tumors
OncLive - 28 Apr 2025Neoadjuvant Dostarlimab Eradicates Disease in 82% of Mismatch Repair–Deficient Solid Tumors ...
Medical miracle? Experimental drug wipes out colorectal cancer completely in trial
Times of India - 03 Feb 2025Medical miracle? Experimental drug wipes out colorectal cancer completely in trial ...
Dostarlimab Gains Breakthrough Therapy Designation for dMMR/MSI-H Rectal Cancer
Docwire News - 19 Dec 2024Dostarlimab Gains Breakthrough Therapy Designation for dMMR/MSI-H Rectal Cancer ...
Real-World Data Support Dostarlimab Combo Benefit in RUBY Trial
Cancer Network - 20 Mar 2025Real-World Data Support Dostarlimab Combo Benefit in RUBY Trial ...
Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer
OncLive - 17 Mar 2025Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer ...
Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer
OncLive - 17 Mar 2025Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer ...
Dr Mirza on Long-Term Response Data for Dostarlimab Plus Chemo in Advanced Endometrial Cancer
OncLive - 26 Mar 2025Dr Mirza on Long-Term Response Data for Dostarlimab Plus Chemo in Advanced Endometrial Cancer ...
European Commission Approves Dostarlimab Plus Chemo for All Advanced/Recurrent Endometrial Cancer
OncLive - 20 Jan 2025European Commission Approves Dostarlimab Plus Chemo for All Advanced/Recurrent Endometrial Cancer ...
Addition of Dostarlimab to Chemo and Niraparib Maintenance Boosts PFS in Advanced Ovarian Cancer
OncLive - 20 Dec 2024Addition of Dostarlimab to Chemo and Niraparib Maintenance Boosts PFS in Advanced Ovarian Cancer ...